ClinicalTrials.gg
RecruitingNCT06755697Updated Apr 24, 2026

Comparative Efficacy of Intra-articular vs. MRI-guided Extra-articular Dextrose Injections in Knee Osteoarthritis Management

An interventional study of Intra-articular US-guided hypertonic dextrose injection, IA group and Extra-articular US-guided injection targeting MRI-positive lesion sites, EA group. in Knee Osteoarthritis, Glucose and Prolotherapy, sponsored by Shin Kong Wu Ho-Su Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Shin Kong Wu Ho-Su Memorial Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Osteoarthritis, Knee with a site in Taiwan — 12 open to participants now, 14 under way, 3 of them phase 3. Osteoarthritis, Knee · Taiwan.

Planned enrollment
40th of 83
60 · median 60
Started
2025
with 6 others
No phase
49 of 89
6 open now
Primary completion
2026-12
later than 6 of 13 live
Registered
78th of 89
by date
Lead sponsor
4 of 89
Shin Kong Wu Ho-Su Memorial Hospital

Among the 89 studies in Osteoarthritis, Knee with a site in Taiwan, this one is the 40th largest by planned enrollment of the 83 interventional ones that give a count, is one of 7 that started in 2025, is one of 49 with no phase, reaches primary completion later than 6 of the 13 other live ones, and was the 78th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 89 studies in Osteoarthritis, Knee with a site in Taiwan are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Osteoarthritis, Knee with a site in Taiwan, or all of them as a file.
02

Study summary

Osteoarthritis (OA) is a serious worldwide public health concern, causing increased disability-adjusted life years (DALY), the reasons of which include rising prevalence of obesity and increasing older populations. The knee is one of the most easily injured joint in the body, and knee OA can become a chronic and disabling condition that pose a threat to not only the patient but also his or her caretakers and healthcare resources. The prevalence of knee OA is 5% - 15% in men over 60 years, and 10% - 25% in women aged more than 60.

Knee OA can result from injuries, diseases, or wear and tear from overuse. It refers to structural changes that affect subchondral bone, articular cartilage, menisci, ligaments, synovium, and other joint structures. Currently, there are several conservative management of knee OA, including physiotherapy (therapeutic exercise, diathermy, electrotherapy), oral or topical medications, intra-articular and extra-articular injections, and radiofrequency.

There are various substances used in injections for knee OA, among which are corticosteroid, platelet-rich plasma (PRP), AmnioFix, exosome, dextrose, and hyaluronic acid (HA). Compared with PRP, AmnioFix, exosome, and HA, which are not covered by the health insurance system, dextrose is a readily available and cost-effective substance. The principle of hypertonic dextrose injection, "prolotherapy", is injection of small volumes of the irritant solution at or around the lesion in order to stimulate fibroblast and vascular proliferation, local tissue healing, reduction of joint instability, thus resulting in pain relief. Previous studies have demonstrated that prolotherapy resulted in clinically meaningful sustained improvement of function and pain in knee OA, and there were no severe adverse events related to hypertonic dextrose injection. A study in 2023 showed that among various dextrose concentrations, higher concentrations demonstrated greater improvement of knee OA, thus 20% dextrose is recommended.

Regarding the site of dextrose injection in knee OA, previous studies demonstrated comparable effects of intra-articular and extra-articular injections. The periarticular injections include points around the knee where periarticular nerves exit the joint capsule, and acupuncture points at upper medial and lateral parts of knee joint. A study in 2024 revealed that prolotherapy combining intra-articular with peri-articular perineural injection resulted in better pain alleviation and improvement in knee joint function in knee OA. There are several choices of imaging modality for recognizing the sites of lesion in knee OA, such as X-ray, ultrasound (US), and magnetic resonance imaging (MRI). Radiography is used to assess osteophytes, joint space narrowing, and subchondral sclerosis, but it has limited ability to detect synovial inflammation, joint effusion, soft tissue abnormalities, and early cartilage damage. US can be used to evaluate synovial fluid and cartilage thickness, but not deep structures (e.g. subchondral bone change, meniscus tear, and ACL tear, etc.). On the other hand, MRI is an optimal and accurate imaging choice for visualizing soft tissue as well as deep structures (e.g. ACL, meniscus, etc) in knee OA. The MRI findings of knee OA includes cartilage damage, meniscus tear, bone marrow lesions, synovitis, ligamentous laxity, and osteophytes. The detection of bony lesions can aid intraosseous Infiltrations, and signs of ligamentous laxity also provides target for ligaments injection. However, there is no current evidence on the effectiveness of prolotherapy targeting knee OA lesion sites according to MRI findings.

Because the effectiveness of prolotherapy targeting lesion sites according to MRI findings has not been well established, the investigators aim to investigate whether injecting dextrose into MRI-positive lesion sites is more beneficial for knee OA comparing to intra-articular injections. The investigators hypothesize that MRI could be a good choice for the guidance of prolotherapy targets.

Read the detailed description

Osteoarthritis (OA) is a serious worldwide public health concern, and there are several conservative management of knee OA. Evidence showed that intra-articular and extra-articular injections are beneficial for knee OA. Compared with PRP, AmnioFix, exosome, and HA, which are not covered by the health insurance system, dextrose is a readily available and cost-effective substance. There are several choices of imaging modality for recognizing the sites of lesion in knee OA, such as X-ray, ultrasound (US), and magnetic resonance imaging (MRI). MRI is an optimal and accurate imaging choice for visualizing soft tissue as well as deep structures. The MRI findings of knee OA includes cartilage damage, meniscus tear, bone marrow lesions, synovitis, ligamentous lesions, and osteophytes. The detection of bony lesions can aid intraosseous Infiltrations. However, there is no current evidence on the effectiveness of prolotherapy targeting knee OA lesion sites according to MRI findings. Thus, the investigators aim to investigate whether injecting dextrose into MRI-positive lesion sites is more beneficial for knee OA comparing to intra-articular injections.

03

Conditions studied

  • Knee Osteoarthritis
  • Glucose
  • Prolotherapy
  • MRI
  • Physical Therapy
  • Rehabilitation
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. . age between 45 to 80 years old;
  2. . meet at least three of the six American College of Rheumatology (ACR) criteria, including age over 50 years, morning stiffness less than 30 minutes, crepitus in passive knee movements, bony tenderness, bony enlargement, and no palpable warmth;
  3. . radiologic grading of 2 or 3 according to Kellgren-Lawrence criteria;
  4. showing willingness to receive prolotherapy.

Exclusion criteria

Exclusion Criteria:

  1. . severe systemic disorders including cancer, uncontrolled diabetes mellitus, sepsis, or cardiopulmonary diseases;
  2. . history of anticoagulation therapy, knee injection over the past three months;
  3. . history of knee surgery or candidates for knee arthroplasty;
  4. . history of drug abuse;
  5. . a history of intolerance to prolotherapy;
  6. . pregnancy;
  7. . infectious arthritis, inflammatory joint diseases, joint dysplasia;
  8. (BMI) greater than 35 kg/m2;
  9. . not suitable or no willing to received MRI examination of the knee.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Intra-articular US-guided hypertonic dextrose injection, IA group

    IA injection: 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected. The ultrasound transducer (L18-4, Philips EPI Q5) is placed transversely over the patient's suprapatellar pouch while the patient lies supine with the knee actively extended and ankle dorsiflexed. The injectate will be injected into the suprapatellar pouch via transverse view, in-plane, lateral-to-medial approach with a 3.8 cm 22-gauge needle under US guidance. Physical therapy: The physical therapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 4 weeks.

    Other: Intra-articular US-guided hypertonic dextrose injection, IA group

  • Active comparator
    Extra-articular US-guided injection targeting MRI-positive lesion sites, EA group.

    Patients in the EA group will receive MRI examination of the knee without contrast. Detailed physical examinations (PE) will also be done for each subject. The PEs include inspection, palpation for local tenderness and crepitus, signs of effusion, assessment of range of motion, provocative meniscal testing, and ligamentous tests for laxity. (16) A total of 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected to the target areas which has been shown abnormal on MRI images with a 3.8 cm 22-gauge needle under US guidance. For lesions of the deep structures or bone marrow lesion, a 7-cm 23 or 21 gauge needles may be used. Same as the IA group, EA hypertonic dextrose injection will be done at the 0, 2nd, and 4th weeks, as well as physical therapy during the first 4 weeks.

    Other: Extra-articular US-guided injection targeting MRI-positive lesion sites, EA group.

Interventions

  • OtherIntra-articular US-guided hypertonic dextrose injection, IA group

    IA injection: 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected. The ultrasound transducer (L18-4, Philips EPI Q5) is placed transversely over the patient's suprapatellar pouch while the patient lies supine with the knee actively extended and ankle dorsiflexed. The injectate will be injected into the suprapatellar pouch via transverse view, in-plane, lateral-to-medial approach with a 3.8 cm 22-gauge needle under US guidance. Physical therapy: The physical therapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 4 weeks.

  • OtherExtra-articular US-guided injection targeting MRI-positive lesion sites, EA group.

    Patients in the EA group will receive MRI examination of the knee without contrast. Detailed physical examinations (PE) will also be done for each subject. The PEs include inspection, palpation for local tenderness and crepitus, signs of effusion, assessment of range of motion, provocative meniscal testing, and ligamentous tests for laxity. A total of 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected to the target areas which has been shown abnormal on MRI images with a 3.8 cm 22-gauge needle under US guidance. For lesions of the deep structures or bone marrow lesion, a 7-cm 23 or 21 gauge needles may be used. Same as the IA group, EA hypertonic dextrose injection will be done at the 0, 2nd, and 4th weeks, as well as physical therapy during the first 4 weeks.

06

What researchers measure

Primary outcomes

  1. The Western Ontario McMaster University Osteoarthritis Index(WOMAC)

    The WOMAC is a questionnaire evaluating the severity of osteoarthritis using pain, stiffness, and function subscales. The WOMAC composite score is constructed as the weighted average of the 3 subscale scores, and it ranges from 0 (worst) to 100 (best) for depicting knee-related quality-of-life. For WOMAC, the minimal clinical important difference (MCID) for knee OA has been reported as a change of 12 points on a 0- to 100-mm visual analog scale. According to previous studies, WOMAC is responsive to clinical changes.

    Time frame: Change between baseline and at 1.5 months, 3 months, 6 months after the beginning of the treatment.

Secondary outcomes

  1. The pain visual analog scale (VAS)

    The pain VAS is obtained using a 100-mm-long horizontal line, with 0 mm on the left, indicating no pain, and 100 mm on the right, indicating very severe pain. The MCID of pain VAS for knee OA ranged from 10 to 19.9 points, according to previous studies.

    Time frame: Change between baseline and at 1.5 months, 3 months, 6 months after the beginning of the treatment.

  2. The 36-item Short Form Health Survey (SF-36)

    The general health status and quality of life will be measured with the SF-36. The SF-36 is composed of 8 subscales including the following components: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each subscale generates a score ranging from 0 to 100, and higher scores indicate better quality of life. A Chinese-language version will be used for which the psychometric properties have been established.

    Time frame: Change between baseline and at 1.5 months, 3 months, 6 months after the beginning of the treatment.

  3. Timed Up and Go (TUG) test

    TUG test is a measure of dynamic balance which has good inter-rater and test-retest reliability. During a TUG test, it is timed when a patient rises from a chair, walks 3 meters, turns and walks back, and then sits down again. The MCID of TUG test has been reported as 3.4 seconds in patients with lumbar stenosis.

    Time frame: Change between baseline and at 1.5 months, 3 months, 6 months after the beginning of the treatment.

  4. Self-assessment of the treatment effect

    Self-assessment of the treatment effect: Patient's evaluation of the treatment effect consists of the answer to one question: "Is the treatment effective?" scored on a Likert scale (very effective=5, effective=4, same=3, worse=2, much worse=1). (This item is not evaluated at baseline.)

    Time frame: Change between baseline and at 1.5 months, 3 months, 6 months after the beginning of the treatment.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 23 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Jan 1, 2025
StartActual
Jan 23, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06755697
Lead sponsor
Shin Kong Wu Ho-Su Memorial Hospital
Responsible party
Lin-Fen Hsieh (Study Principal Investigator, Shin Kong Wu Ho-Su Memorial Hospital) — Principal investigator
First posted
Jan 1, 2025
Start date
Jan 23, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 24, 2026

Study contacts

Lin-Fen Hsieh
Contact
M001026@ms.skh.org.tw
+886-28332211 ext. 2538
Lin-Fen Hsieh
principal investigator · Shin Kong Wu Ho-Su Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion